<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Bras Nefrol</journal-id><journal-id journal-id-type="iso-abbrev">J Bras Nefrol</journal-id><journal-id journal-id-type="publisher-id">jbn</journal-id><journal-title-group><journal-title>Jornal Brasileiro de Nefrologia</journal-title></journal-title-group><issn pub-type="ppub">0101-2800</issn><issn pub-type="epub">2175-8239</issn><publisher><publisher-name>Sociedade Brasileira de Nefrologia</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408600</article-id><article-id pub-id-type="pmc">PMC12101797</article-id>
<article-id pub-id-type="other">00701</article-id><article-id pub-id-type="doi">10.1590/2175-8239-JBN-2024-0123en</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Communication</subject></subj-group></article-categories><title-group><article-title>KIM-1 as a biomarker of kidney tubular damage in normoalbuminuric patients with type 2 diabetes mellitus and insulin resistance</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-2539-2710</contrib-id><name><surname>de Oliveira</surname><given-names>Laura Eduarda</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role>data tabulation</role><role>analysis and interpretation of results</role><role>manuscript drafting</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6676-2970</contrib-id><name><surname>Paniz</surname><given-names>Cl&#x000f3;vis</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role>academic supervision and manuscript revision</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3072-5080</contrib-id><name><surname>Moresco</surname><given-names>Rafael Noal</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role>academic supervision and manuscript revision</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8601-5630</contrib-id><name><surname>de Carvalho</surname><given-names>Jos&#x000e9; Antonio Mainardi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role>data collection and interpretation of results</role><role>academic supervision and manuscript revision</role></contrib></contrib-group><aff id="aff1">
<label>1</label>Universidade Federal de Santa Maria, Centro de Ci&#x000ea;ncias da Sa&#x000fa;de, Programa de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Ci&#x000ea;ncias Farmac&#x000ea;uticas, Santa Maria, RS, Brazil.</aff><aff id="aff2">
<label>2</label>Universidade Federal de Santa Maria, Centro de Ci&#x000ea;ncias da Sa&#x000fa;de, Laborat&#x000f3;rio de Pesquisa em An&#x000e1;lises Cl&#x000ed;nicas Aplicadas (LAPACA), Departamento de An&#x000e1;lises Cl&#x000ed;nicas e Toxicol&#x000f3;gicas, Santa Maria, RS, Brazil.</aff><author-notes><corresp id="c001">
<bold>Correspondence to:</bold> Jos&#x000e9; Antonio Mainardi de Carvalho. Email: <email>jose.mainardi@ufsm.br</email>
</corresp><fn fn-type="COI-statement"><p><bold>Conflict of Interest:</bold> On behalf of all the authors, the corresponding author declares that there are no conflicts of interest.</p></fn><fn fn-type="edited-by"><p><bold>Editor-in-chief:</bold> Miguel C. Riella.</p></fn><fn fn-type="edited-by" id="FN1"><p><bold>Associate Editor:</bold> Viviane Calice-Silva.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>5</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><season>Jul-Sep</season><year>2025</year></pub-date><volume>47</volume><issue>3</issue><elocation-id>e20240123</elocation-id><history><date date-type="received"><day>11</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2025</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Introduction:</title><p>Insulin resistance (IR) is associated with diabetic kidney disease (DKD), and normoalbuminuric patients may present with renal tubular damage associated with insulin resistance (RTDAIR). In this context, the kidney injury molecule-1 (KIM-1) emerges as a useful biomarker for assessing tubular damage.</p></sec><sec><title>Objective:</title><p>To investigate the role of KIM-1 in the detection of RTDAIR in normoalbuminuric patients, as well as its relationship with HOMA-IR.</p></sec><sec><title>Methodology:</title><p>This was a cross-sectional study involving 82 normoalbuminuric patients with T2DM, divided into two groups according to HOMA-IR. Laboratory tests were performed, and data were analyzed using Student's t-test. A p-value &#x0003c; 0.05 was considered significant.</p></sec><sec><title>Results:</title><p>Patients with higher IR (HOMA-IR &#x02265; 2.77) had increased urinary KIM-1 (uKIM-1) concentrations (113.3 &#x000b1; 65.0 ng/g creatinine), which may indicate incipient DKD.</p></sec><sec><title>Conclusion:</title><p>Increased HOMA-IR may be related to elevated uKIM-1 levels, suggesting that IR contributes to the development of RTDAIR. Furthermore, uKIM-1 may serve as a useful biomarker for its detection.</p></sec></abstract><kwd-group><title>Keywords:</title><kwd>Diabetes</kwd><kwd>Mellitus</kwd><kwd>Kidney Disease</kwd><kwd>Insulin Resistance</kwd><kwd>Biomarkers</kwd></kwd-group><funding-group><award-group><funding-source>Funda&#x000e7;&#x000e3;o Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior</funding-source><award-id>88887.921363/2023-00</award-id></award-group></funding-group><counts><fig-count count="02"/><table-count count="02"/><ref-count count="15"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Insulin resistance is a condition that causes hyperglycemia and contributes to the development of type 2 diabetes mellitus (T2DM)<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>. These alterations could be detected using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), which allows glycemic control and insulin resistance to be assessed<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>.</p><p>Patients with T2DM are more likely to develop diabetic kidney disease (DKD), diagnosed by albumin/creatinine ratio (ACR) levels. However, some studies have found the presence of renal tubular damage associated with changes in insulin resistance (RTDAIR) even in patients with ACR values within the normal range<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>. In this context, the kidney injury molecule (KIM-1) has been associated with changes in renal tubules, regardless of ACR levels<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>. Thus, the aim of this study was to investigate the role of KIM-1 in detecting tubular damage in T2DM patients and its relationship with the degree of insulin resistance, as assessed by HOMA-IR.</p></sec><sec sec-type="methods"><title>Methods</title><p>This study included patients (n = 121) previously diagnosed with T2DM undergoing treatment at the outpatient clinic of the <italic>Hospital Universit&#x000e1;rio de Santa Maria</italic>, located in Santa Maria, Rio Grande do Sul, Brazil. The diagnosis of T2DM was established according to the American Diabetes Association (ADA) and the Brazilian Diabetes Society (SBD, in Portuguese) criteria, which consider blood glucose and glycated hemoglobin (HbA1c) values. Exclusion criteria included an ACR greater than 30 mg/g creatinine, urinary tract diseases, neoplasms, uncontrolled thyroid disorders, liver diseases, infections or inflammatory conditions, pregnancy, kidney transplantation, and the use of nephrotoxic drugs.</p><p>Of the initial 121 patients, 39 were excluded due to ACR concentrations exceeding 30 mg/g creatine. The remaining 82 patients were stratified into two groups based on HOMA-IR, following a study of a Brazilian population<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>: HOMA-IR &#x02264; 2.77 (n = 32) and HOMA-IR &#x0003e; 2.77 (n = 50). The presence of incipient DKD was determined using a uKIM-1 cut-off value (&#x0003e;109 ng/g creatinine), previously established for a Brazilian T2DM population, allowing discrimination between patients with and without incipient DKD<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup>. This study was approved by the Ethics Committee for Human Studies of the Institution, under protocol number C.A.A.E 12303113.0.0000.5346, and all patients signed a consent form.</p><p>Blood samples were collected after overnight fasting using the venipuncture technique in Vacutainer&#x000ae; tubes (BD Diagnostics, Plymouth, UK). The samples were then centrifuged at 3,000 rpm for 15 minutes. In addition, all participants provided a urine sample, which was centrifuged at 1,500 rpm for 5 minutes. HbA1c concentrations were determined in whole blood samples by a chromatographic method with the D-10&#x000ae; analyzer (Bio-Rad, California, USA). Measurements of glucose, urinary creatinine and ACR were performed on the Dimension RxL Max&#x000ae; automated analyzer (Siemens Healthcare Diagnostics, Malvern, USA). uKIM-1 levels were analyzed using commercial sandwich ELISA kits (R&#x00026;D systems, Minneapolis, MN, USA). Insulin levels were measured using the Cobas&#x000ae; 6000 analyzer (Roche Diagnostics, USA). HOMA-IR was calculated according to the equation: fasting insulin [&#x003bc;U/l] x fasting glucose [mmol/l]/22.5. The triglyceride-glucose index (TyG) was determined by the equation: ln [fasting triglycerides (mg/dl) x fasting glucose (mg/dl)]/2. The glomerular filtration rate (GFR) was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.</p><p>Data were presented as mean and standard deviation (SD) for continuous variables. The distribution of variables was assessed using the Kolmogorov-Smirnov test. Student&#x02019;s t-test was used to compare continuous variables, while the chi-square test was used for categorical variables. Statistical differences between groups were also assessed using Student&#x02019;s t-test. A p-value &#x0003c; 0.05 was considered statistically significant. Statistical analyses were performed using GraphPad software (San Diego, CA, USA).</p></sec><sec sec-type="results"><title>Results</title><p>General data for the study population are described in <xref rid="T1" ref-type="table">Table 1</xref>. In the present study, patients in both groups had ACR values within the normal range, which, in theory, would indicate the absence of DKD. However, although ACR is one of the criteria adopted for diagnosing DKD, this condition may occur even with normal ACR results. The group with HOMA-IR &#x02265; 2.77 had a uKIM-1 value of 113.3 &#x000b1; 65.0 ng/g creatinine, higher than the results found for the group with HOMA-IR &#x0003c; 2.77 which, in turn, presented a uKIM-1 concentration of 84.4 &#x000b1; 50.0 ng/g creatinine (<xref rid="F1" ref-type="fig">Figure 1</xref>). This difference represented an increase of approximately 35% in uKIM-1 results for the group with greater insulin resistance, which was statistically significant. In addition, patients with uKIM-1 &#x0003e;109 ng/g creatinine were observed in both groups, with a prevalence of 40% in the HOMA-IR &#x02265; 2.77 group and 15.6|% in the HOMA-IR &#x0003c; 2.77 group (p = 0.0193).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><title>Epidemiological and biochemical data of the study participants</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">HOMA-IR index &#x0003c; 2.77</th><th align="center" valign="top" rowspan="1" colspan="1">HOMA-IR index &#x02265; 2.77</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="center" valign="top" rowspan="1" colspan="1">63.7 &#x000b1; 11.0</td><td align="center" valign="top" rowspan="1" colspan="1">56.6 &#x000b1; 13.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">27.8 &#x000b1; 4.3</td><td align="center" valign="top" rowspan="1" colspan="1">33.2 &#x000b1; 5.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male<break/>Use of oral antihypertensives</td><td align="center" valign="top" rowspan="1" colspan="1">13 (40.6%)<break/>24 (75%)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (30.0%)<break/>34 (68%)</td><td align="center" valign="top" rowspan="1" colspan="1">0.322<break/>0.496</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fasting glucose (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">119.8 &#x000b1; 30.7</td><td align="center" valign="top" rowspan="1" colspan="1">138.4 &#x000b1; 39.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c (%)</td><td align="center" valign="top" rowspan="1" colspan="1">6.7 &#x000b1; 1.2</td><td align="center" valign="top" rowspan="1" colspan="1">7.9 &#x000b1; 2.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insulin (uUI/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">6.1 &#x000b1; 2.1</td><td align="center" valign="top" rowspan="1" colspan="1">21.5 &#x000b1; 8.9</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total cholesterol (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">174.2 &#x000b1; 33.6</td><td align="center" valign="top" rowspan="1" colspan="1">170.8 &#x000b1; 27.9</td><td align="center" valign="top" rowspan="1" colspan="1">0.627</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL cholesterol (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">53.6 &#x000b1; 12.0</td><td align="center" valign="top" rowspan="1" colspan="1">44.6 &#x000b1; 11.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">121.9 &#x000b1; 56.7</td><td align="center" valign="top" rowspan="1" colspan="1">140.4 &#x000b1; 60.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.177</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine (&#x000b5;mol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">1.1 &#x000b1; 0.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.9 &#x000b1; 0.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.095</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TyG</td><td align="center" valign="top" rowspan="1" colspan="1">4.7 &#x000b1; 0.2</td><td align="center" valign="top" rowspan="1" colspan="1">4.9 &#x000b1; 0.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td><td align="center" valign="top" rowspan="1" colspan="1">1.7 &#x000b1; 0.5</td><td align="center" valign="top" rowspan="1" colspan="1">7.3 &#x000b1; 3.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CKD-EPI (mL/min/1.73m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">73.1 &#x000b1; 19.8</td><td align="center" valign="top" rowspan="1" colspan="1">76.02 &#x000b1; 21.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.539</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">uCrea (mmol/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">0.9 &#x000b1; 0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.9 &#x000b1; 0.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.477</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACR (mg/g creat)</td><td align="center" valign="top" rowspan="1" colspan="1">7.5 &#x000b1; 4.3</td><td align="center" valign="top" rowspan="1" colspan="1">9.0 &#x000b1; 6.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.242</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">uKIM-1(ng/g creat)</td><td align="center" valign="top" rowspan="1" colspan="1">84.4 &#x000b1; 50.0</td><td align="center" valign="top" rowspan="1" colspan="1">113.3 &#x000b1; 65.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.044</td></tr></tbody></table><table-wrap-foot><fn id="T1FN1"><p>Abbreviations &#x02013; BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high-density cholesterol; TyG index, triglyceride-glucose index; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; CKD-EPI equation, creatinine equation from the Chronic Kidney Disease Epidemiology Collaboration; uCrea, urinary creatinine; ACR, albumin/creatinine ratio; uKIM-1, urinary kidney injury molecule-1. Notes &#x02013; Continuous data are expressed as mean &#x000b1; standard deviation. Categorical data are expressed as number of individuals and percentage (in parentheses).</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><title>uKIM-1 values in T2DM patients with HOMA-IR &#x0003c; 2.77 and HOMA-IR &#x02265; 2.77. Data are expressed as mean &#x000b1; standard deviation. Statistical differences between groups were assessed using Student&#x02019;s t-test.</title></caption><graphic xlink:href="2175-8239-jbn-47-3-e20240123-gf01" position="float"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>The effects of hyperglycemia are known to be associated with various dysfunctions that could damage kidney structures and contribute to the development of DKD. The etiology of this condition is based on lesions caused by hyperfiltration of the glomerular filtration barrier, oxidative stress, and glomerular mesangial expansion, factors associated with poor glycemic control and the consequent increase in ACR concentrations<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup>. It is therefore essential to assess the patient&#x02019;s clinical condition using laboratory tests. In this context, uKIM-1 may be a relevant indicator, associated with insulin resistance biomarkers such as the HOMA-IR index, since KIM-1 could help detect tubular alterations before the concentration of ACR increases.</p><p>The gold standard for diagnosing DKD is the measurement of ACR, a biomarker of glomerular damage whose increase is the first sign of renal insufficiency<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup>. However, studies have indicated the presence of histological alterations in the glomerular basement membrane in biopsy samples, even at ACR concentrations within the normal range<sup>
<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>
</sup>.</p><p>Considering that the effects of kidney injury caused by T2DM may lead to serious complications, it is crucial to screen the most susceptible patients or those in the early stages of the disease. Early diagnosis would enable the adoption of measures to prevent the development of DKD, and avoid serious and irreversible consequences<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup>.</p><p>Therefore, efforts have been made to identify new biomarkers capable of detecting early kidney damage, including uKIM-1<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>. The use of this protein as a biomarker for RTDAIR offers several advantages, such as the ability to indicate the presence of tubulointerstitial injuries, since tubular injuries often precede glomerular damage. Furthermore, under normal conditions, uKIM-1 is undetectable in urine, which contributes to the increased specificity of this marker<sup>
<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>
</sup>.</p><p>The present study has some limitations, including the relatively low number of participants, the absence of sample size calculation, and the lack of data related to pharmacological and non-pharmacological treatments. However, we have demonstrated that individuals with greater insulin resistance may exhibit increased tubular damage, as evidenced by elevated uKIM-1 levels, even in the absence of glomerular damage (according to normal ACR values). As hyperglycemia is one of the main contributing factors to the development of renal tubular damage, individuals with greater insulin resistance tend to have poorer glycemic control<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup>.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>In this study, we observed that patients with greater insulin resistance, indicated by HOMA-IR values, exhibited higher uKIM-1 concentrations, which may indicate the occurrence of kidney tubular damage among normoalbuminuric patients. uKIM-1, along with ACR, may be essential for identifying the presence of lesions in different nephron sites, such as the glomerulus and renal tubules, respectively. Therefore, the laboratory analysis of uKIM-1 has the potential to contribute to a more detailed and in-depth assessment of renal tubular alterations.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by scholarships from the <italic>Funda&#x000e7;&#x000e3;o Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior</italic> (CAPES; grant no. 88887.921363/2023-00).</p></ack><sec sec-type="data-availability" specific-use="data-available-upon-request"><title>Data Availability</title><p>The data for substantiating the findings of this manuscript are available with the corresponding author and can be made available on request.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>W</given-names></name>
<name><surname>Jiang</surname><given-names>W</given-names></name>
<name><surname>Guo</surname><given-names>S</given-names></name>
</person-group><article-title>Regulation of macronutrients in insulin resistance and glucose homeostasis during type 2 diabetes mellitus.</article-title><source>Nutrients.</source><year>2023</year><volume>15</volume><issue>21</issue><fpage>4671</fpage><pub-id pub-id-type="doi">10.3390/nu15214671</pub-id><pub-id pub-id-type="pmid">37960324</pub-id>
</element-citation></ref><ref id="B2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okita</surname><given-names>K</given-names></name>
<name><surname>Iwahashi</surname><given-names>H</given-names></name>
<name><surname>Kozawa</surname><given-names>J</given-names></name>
<name><surname>Okauchi</surname><given-names>Y</given-names></name>
<name><surname>Funahashi</surname><given-names>T</given-names></name>
<name><surname>Imagawa</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy.</article-title><source>Endocr J.</source><year>2013</year><volume>60</volume><issue>3</issue><fpage>283</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1507/endocrj.EJ12-0320</pub-id><pub-id pub-id-type="pmid">23149658</pub-id>
</element-citation></ref><ref id="B3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>C</given-names></name>
<name><surname>Hu</surname><given-names>C</given-names></name>
<name><surname>Han</surname><given-names>Y</given-names></name>
<name><surname>Zhao</surname><given-names>L</given-names></name>
<name><surname>Zhu</surname><given-names>X</given-names></name>
<etal/>
</person-group><article-title>Normoalbuminuric diabetic kidney disease.</article-title><source>Front Med.</source><year>2017</year><volume>11</volume><issue>3</issue><fpage>310</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s11684-017-0542-7</pub-id><pub-id pub-id-type="pmid">28721497</pub-id>
</element-citation></ref><ref id="B4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karmakova</surname><given-names>TA</given-names></name>
<name><surname>Sergeeva</surname><given-names>NS</given-names></name>
<name><surname>Kanukoev</surname><given-names>KY</given-names></name>
<name><surname>Alekseev</surname><given-names>BY</given-names></name>
<name><surname>Kaprin</surname><given-names>AD</given-names></name>
</person-group><article-title>Kidney injury molecule 1 (KIM-1): a multifunctional glycoprotein and biological marker.</article-title><source>Sovrem Tekhnologii Med.</source><year>2021</year><volume>13</volume><issue>3</issue><fpage>64</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.17691/stm2021.13.3.08</pub-id><pub-id pub-id-type="pmid">34603757</pub-id>
</element-citation></ref><ref id="B5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Geloneze</surname><given-names>B</given-names></name>
<name><surname>Repetto</surname><given-names>EM</given-names></name>
<name><surname>Geloneze</surname><given-names>SR</given-names></name>
<name><surname>Tambascia</surname><given-names>MA</given-names></name>
<name><surname>Ermetice</surname><given-names>MN</given-names></name>
</person-group><article-title>The threshold value for insulin resistance (HOMA-IR) in an admixtured population.</article-title><source>Diabetes Res Clin Pract.</source><year>2006</year><volume>72</volume><issue>2</issue><fpage>219</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2005.10.017</pub-id><pub-id pub-id-type="pmid">16310881</pub-id>
</element-citation></ref><ref id="B6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De</surname><given-names>Carvalho JAM</given-names></name>
<name><surname>Tatsch</surname><given-names>E</given-names></name>
<name><surname>Hausen</surname><given-names>BS</given-names></name>
<name><surname>Bollick</surname><given-names>YS</given-names></name>
<name><surname>Torbitz</surname><given-names>VD</given-names></name>
<name><surname>Guarda</surname><given-names>NS</given-names></name>
<etal/>
</person-group><article-title>Evaluation of the diagnostic characteristics of urinary kidney injury molecule 1 (uKIM-1) and uKIM-1/creatinine ratio in the assessment of incipient diabetic kidney disease.</article-title><source>Clin Chem Lab Med.</source><year>2015</year><volume>53</volume><issue>2</issue><fpage>e51</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1515/cclm-2014-0655</pub-id><pub-id pub-id-type="pmid">25153602</pub-id>
</element-citation></ref><ref id="B7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cole</surname><given-names>JB</given-names></name>
<name><surname>Florez</surname><given-names>JC</given-names></name>
</person-group><article-title>Genetics of diabetes mellitus and diabetes complications.</article-title><source>Nat Rev Nephrol.</source><year>2020</year><volume>16</volume><issue>7</issue><fpage>377</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/s41581-020-0278-5</pub-id><pub-id pub-id-type="pmid">32398868</pub-id>
</element-citation></ref><ref id="B8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>KDOQI.</collab>
</person-group><article-title>KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease.</article-title><source>Am J Kidney Dis.</source><year>2007</year><volume>49</volume><issue>Suppl 2</issue><fpage>S12</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2006.12.005</pub-id><pub-id pub-id-type="pmid">17276798</pub-id>
</element-citation></ref><ref id="B9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moriya</surname><given-names>T</given-names></name>
<name><surname>Suzuki</surname><given-names>Y</given-names></name>
<name><surname>Inomata</surname><given-names>S</given-names></name>
<name><surname>Iwano</surname><given-names>M</given-names></name>
<name><surname>Kanauchi</surname><given-names>M</given-names></name>
<name><surname>Haneda</surname><given-names>M</given-names></name>
</person-group><article-title>Renal histological heterogeneity and functional progress in normoalbuminuric and microalbuminuric Japanese patients with type 2 diabetes.</article-title><source>BMJ Open Diabetes Res Care.</source><year>2014</year><volume>2</volume><issue>1</issue><fpage>e000029</fpage><pub-id pub-id-type="doi">10.1136/bmjdrc-2014-000029</pub-id><pub-id pub-id-type="pmid">25452869</pub-id>
</element-citation></ref><ref id="B10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Comai</surname><given-names>G</given-names></name>
<name><surname>Malvi</surname><given-names>D</given-names></name>
<name><surname>Angeletti</surname><given-names>A</given-names></name>
<name><surname>Vasuri</surname><given-names>F</given-names></name>
<name><surname>Valente</surname><given-names>S</given-names></name>
<name><surname>Ambrosi</surname><given-names>F</given-names></name>
<etal/>
</person-group><article-title>Histological evidence of diabetic kidney disease precede clinical diagnosis.</article-title><source>Am J Nephrol.</source><year>2019</year><volume>50</volume><issue>1</issue><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1159/000500353</pub-id><pub-id pub-id-type="pmid">31167184</pub-id>
</element-citation></ref><ref id="B11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>C-Y</given-names></name>
<name><surname>Yoo</surname><given-names>T-H</given-names></name>
</person-group><article-title>Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease.</article-title><source>Diabetes Metab J.</source><year>2022</year><volume>46</volume><issue>2</issue><fpage>181</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.4093/dmj.2021.0329</pub-id><pub-id pub-id-type="pmid">35385633</pub-id>
</element-citation></ref><ref id="B12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moresco</surname><given-names>RN</given-names></name>
<name><surname>Bochi</surname><given-names>GV</given-names></name>
<name><surname>Stein</surname><given-names>CS</given-names></name>
<name><surname>Carvalho</surname><given-names>JA</given-names></name>
<name><surname>Cembranel</surname><given-names>BM</given-names></name>
<name><surname>Bollick</surname><given-names>YS</given-names></name>
</person-group><article-title>Urinary kidney injury molecule-1 in renal disease.</article-title><source>Clin Chim Acta.</source><year>2018</year><volume>487</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2018.09.011</pub-id><pub-id pub-id-type="pmid">30201372</pub-id>
</element-citation></ref><ref id="B13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>L</given-names></name>
<name><surname>Mann</surname><given-names>D</given-names></name>
<name><surname>Imig</surname><given-names>JD</given-names></name>
<name><surname>Emmett</surname><given-names>N</given-names></name>
<etal/>
</person-group><article-title>Glomerular expression of kidney injury molecule-1 and podocytopenia in diabetic glomerulopathy.</article-title><source>Am J Nephrol.</source><year>2011</year><volume>34</volume><issue>3</issue><fpage>268</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1159/000330187</pub-id><pub-id pub-id-type="pmid">21822010</pub-id>
</element-citation></ref><ref id="B14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guarda</surname><given-names>NS</given-names></name>
<name><surname>Bollick</surname><given-names>YS</given-names></name>
<name><surname>de middle</surname><given-names>JAM</given-names></name>
<name><surname>Premaor</surname><given-names>MO</given-names></name>
<name><surname>Comim</surname><given-names>FV</given-names></name>
<name><surname>Moresco</surname><given-names>RN</given-names></name>
</person-group><article-title>High serum uric acid is associated with tubular damage and kidney inflammation in patients with type 2 diabetes.</article-title><source>Dis Markers.</source><year>2019</year><volume>2019</volume><fpage>6025804</fpage><pub-id pub-id-type="doi">10.1155/2019/6025804</pub-id><pub-id pub-id-type="pmid">31110596</pub-id>
</element-citation></ref><ref id="B15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tahapary</surname><given-names>DL</given-names></name>
<name><surname>Pratisthita</surname><given-names>LB</given-names></name>
<name><surname>Fitri</surname><given-names>NA</given-names></name>
<name><surname>Marcella</surname><given-names>C</given-names></name>
<name><surname>Wafa</surname><given-names>S</given-names></name>
<name><surname>Kurniawan</surname><given-names>F</given-names></name>
<etal/>
</person-group><article-title>Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and Tryglyceride/glucose index.</article-title><source>Diabetes Metab Syndr.</source><year>2022</year><volume>16</volume><issue>8</issue><fpage>102581</fpage><pub-id pub-id-type="doi">10.1016/j.dsx.2022.102581</pub-id><pub-id pub-id-type="pmid">35939943</pub-id>
</element-citation></ref></ref-list></back><sub-article article-type="translation" id="s1" xml:lang="pt"><front-stub><article-id pub-id-type="doi">10.1590/2175-8239-JBN-2024-0123pt</article-id><article-categories><subj-group subj-group-type="heading"><subject>Comunica&#x000e7;&#x000e3;o Breve</subject></subj-group></article-categories><title-group><article-title>KIM-1 como biomarcador de les&#x000e3;o tubular renal em pacientes com diabetes <italic>mellitus</italic> tipo 2 normoalbumin&#x000fa;ricos e com resist&#x000ea;ncia &#x000e0; insulina</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-2539-2710</contrib-id><name><surname>Oliveira</surname><given-names>Laura Eduarda de</given-names></name><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>2</sup>
</xref><role>tabula&#x000e7;&#x000e3;o dos dados</role><role>an&#x000e1;lise e interpreta&#x000e7;&#x000e3;o dos resultados</role><role>elabora&#x000e7;&#x000e3;o do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6676-2970</contrib-id><name><surname>Paniz</surname><given-names>Cl&#x000f3;vis</given-names></name><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>2</sup>
</xref><role>supervis&#x000e3;o acad&#x000ea;mica e revis&#x000e3;o do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3072-5080</contrib-id><name><surname>Moresco</surname><given-names>Rafael Noal</given-names></name><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref><role>supervis&#x000e3;o acad&#x000ea;mica e revis&#x000e3;o do manuscrito</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8601-5630</contrib-id><name><surname>Carvalho</surname><given-names>Jos&#x000e9; Antonio Mainardi de</given-names></name><xref rid="aff3" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>2</sup>
</xref><role>obten&#x000e7;&#x000e3;o de dados e interpreta&#x000e7;&#x000e3;o dos resultados</role><role>supervis&#x000e3;o acad&#x000ea;mica e revis&#x000e3;o do manuscrito</role></contrib></contrib-group><aff id="aff3">
<label>1</label>Universidade Federal de Santa Maria, Centro de Ci&#x000ea;ncias da Sa&#x000fa;de, Programa de P&#x000f3;s-Gradua&#x000e7;&#x000e3;o em Ci&#x000ea;ncias Farmac&#x000ea;uticas, Santa Maria, RS, Brasil.</aff><aff id="aff4">
<label>2</label>Universidade Federal de Santa Maria, Centro de Ci&#x000ea;ncias da Sa&#x000fa;de, Laborat&#x000f3;rio de Pesquisa em An&#x000e1;lises Cl&#x000ed;nicas Aplicadas (LAPACA), Departamento de An&#x000e1;lises Cl&#x000ed;nicas e Toxicol&#x000f3;gicas, Santa Maria, RS, Brasil.</aff><author-notes><corresp id="c002">
<bold>Correspond&#x000ea;ncia para:</bold> Jos&#x000e9; Antonio Mainardi de Carvalho. E-mail: <email>jose.mainardi@ufsm.br</email>
</corresp><fn fn-type="COI-statement"><p><bold>Conflito de Interesse:</bold> Em nome de todos os autores, o autor correspondente declara n&#x000e3;o haver conflitos de interesses.</p></fn><fn fn-type="edited-by"><p><bold>Editor-chefe:</bold> Miguel C. Riella.</p></fn><fn fn-type="edited-by" id="FN3"><p><bold>Editor Associado:</bold> Viviane Calice-Silva.</p></fn></author-notes><abstract><title>Resumo</title><sec><title>Introdu&#x000e7;&#x000e3;o:</title><p>A resist&#x000ea;ncia &#x000e0; insulina (RI) est&#x000e1; associada &#x000e0; doen&#x000e7;a renal diab&#x000e9;tica (DRD) e pacientes normoalbumin&#x000fa;ricos podem apresentar les&#x000e3;o tubular renal associada &#x000e0; resist&#x000ea;ncia &#x000e0; insulina (RTDAIR). Nesse contexto, a mol&#x000e9;cula de les&#x000e3;o renal-1 (KIM-1) se apresenta como um marcador &#x000fa;til para a avalia&#x000e7;&#x000e3;o da les&#x000e3;o tubular.</p></sec><sec><title>Objetivo:</title><p>Investigar o papel do KIM-1 na detec&#x000e7;&#x000e3;o de RTDAIR em pacientes normoalbumin&#x000fa;ricos, bem como sua rela&#x000e7;&#x000e3;o com o HOMA-IR.</p></sec><sec><title>Metodologia:</title><p>Estudo transversal envolvendo 82 pacientes com DM2 normoalbumin&#x000fa;ricos, divididos em dois grupos pelo HOMA-IR. Foram realizados exames laboratoriais e os dados foram analisados utilizando o teste <italic>t</italic> de Student. Um valor de p &#x0003c; 0,05 foi considerado significativo.</p></sec><sec><title>Resultados:</title><p>Pacientes com maior RI (HOMA-IR &#x02265; 2,77) apresentaram concentra&#x000e7;&#x000f5;es de KIM-1 urin&#x000e1;rio (uKIM-1) mais elevadas (113,3 &#x000b1; 65,0 ng/g creatinina), o que pode indicar DRD incipiente.</p></sec><sec><title>Conclus&#x000e3;o:</title><p>O aumento do HOMA-IR pode estar relacionado &#x000e0; eleva&#x000e7;&#x000e3;o do uKIM-1, sugerindo que a RI contribui para o desenvolvimento da RTDAIR. Al&#x000e9;m disso, o uKIM-1 pode ser um marcador &#x000fa;til para sua detec&#x000e7;&#x000e3;o.</p></sec></abstract><kwd-group><title>Descritores:</title><kwd>Diabetes</kwd><kwd>Mellitus</kwd><kwd>Nefropatias</kwd><kwd>Resist&#x000ea;ncia &#x000e0; Insulina</kwd><kwd>Biomarcadores</kwd></kwd-group></front-stub><body><sec sec-type="intro"><title>Introdu&#x000e7;&#x000e3;o</title><p>A resist&#x000ea;ncia &#x000e0; insulina &#x000e9; uma condi&#x000e7;&#x000e3;o que causa hiperglicemia e contribui para o desenvolvimento do diabetes mellitus tipo 2 (DM2)<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>. Estas altera&#x000e7;&#x000f5;es podem ser detectadas por meio do Modelo de Avalia&#x000e7;&#x000e3;o da Homeostasia da Resist&#x000ea;ncia &#x000e0; Insulina (HOMA-IR), que permite avaliar o controle glic&#x000ea;mico e a resist&#x000ea;ncia &#x000e0; insulina<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>.</p><p>Pacientes com DM2 apresentam maior suscetibilidade ao desenvolvimento de doen&#x000e7;a renal diab&#x000e9;tica (DRD), diagnosticada pelos n&#x000ed;veis da rela&#x000e7;&#x000e3;o albumina/creatinina (RAC). Entretanto, alguns estudos constataram a presen&#x000e7;a de les&#x000e3;o tubular renal associada a altera&#x000e7;&#x000f5;es na resist&#x000ea;ncia &#x000e0; insulina (RTDAIR) mesmo em pacientes com valores de RAC dentro da normalidade<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>. Nesse contexto, a mol&#x000e9;cula de les&#x000e3;o renal (KIM-1) tem sido associada a mudan&#x000e7;as nos t&#x000fa;bulos renais, independentemente do n&#x000ed;vel da RAC<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup>. Assim, o objetivo deste estudo foi investigar o papel do KIM-1 na detec&#x000e7;&#x000e3;o da les&#x000e3;o tubular em pacientes com DM2 e sua rela&#x000e7;&#x000e3;o com o grau de resist&#x000ea;ncia &#x000e0; insulina, avaliado pelo HOMA-IR.</p></sec><sec sec-type="methods"><title>M&#x000e9;todos</title><p>Este estudo incluiu pacientes (n = 121) previamente diagnosticados com DM2 em tratamento no ambulat&#x000f3;rio do Hospital Universit&#x000e1;rio de Santa Maria, localizado em Santa Maria, Rio Grande do Sul, Brasil. O diagn&#x000f3;stico de DM2 foi estabelecido conforme os crit&#x000e9;rios da <italic>American Diabetes Association</italic> (ADA) e da Sociedade Brasileira de Diabetes (SBD), que consideram os valores de glicemia e hemoglobina glicada (HbA1c). Os crit&#x000e9;rios de exclus&#x000e3;o inclu&#x000ed;ram uma RAC superior a 30 mg/g de creatinina, doen&#x000e7;as do trato urin&#x000e1;rio, neoplasias, doen&#x000e7;as da tireoide n&#x000e3;o controladas, doen&#x000e7;as hep&#x000e1;ticas, infec&#x000e7;&#x000f5;es ou condi&#x000e7;&#x000f5;es inflamat&#x000f3;rias, gravidez, transplante renal e o uso de f&#x000e1;rmacos nefrot&#x000f3;xicos.</p><p>Dos 121 pacientes iniciais, 39 foram exclu&#x000ed;dos por apresentarem concentra&#x000e7;&#x000f5;es de RAC superiores a 30 mg/g creatina. Os 82 pacientes restantes foram estratificados em dois grupos com base no HOMA-IR seguindo um estudo de uma popula&#x000e7;&#x000e3;o brasileira<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup>: HOMA-IR &#x02264; 2,77 (n = 32) e HOMA-IR &#x0003e; 2,77 (n = 50). A presen&#x000e7;a de DRD incipiente foi determinada considerando um ponto de corte para uKIM-1 (&#x0003e;109 ng/g creatinina), previamente estabelecido para uma popula&#x000e7;&#x000e3;o DM2 no Brasil, permitindo a discrimina&#x000e7;&#x000e3;o entre pacientes com e sem DRD incipiente<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup>. O presente estudo foi aprovado pelo Comite de &#x000c9;tica para Estudos em Seres Humanos da institui&#x000e7;&#x000e3;o, sob o n&#x000fa;mero C.A.A.E 12303113.0.0000.5346, e todos os pacientes assinaram um formul&#x000e1;rio de consentimento.</p><p>As amostras de sangue foram coletadas ap&#x000f3;s jejum noturno utilizando a t&#x000e9;cnica de pun&#x000e7;&#x000e3;o venosa em tubos Vacutainer&#x000ae; (<italic>BD Diagnostics</italic>, Plymouth, Reino Unido). Em seguida, foram centrifugadas a 3.000 rpm durante 15 minutos. Al&#x000e9;m disso, todos os participantes forneceram uma amostra de urina, que foi submetida &#x000e0; centrifuga&#x000e7;&#x000e3;o a 1.500 rpm por 5 minutos. A concentra&#x000e7;&#x000e3;o de HbA1c foi determinada em amostras de sangue total por meio de um m&#x000e9;todo cromatogr&#x000e1;fico, utilizando o analisador D-10&#x000ae; (<italic>Bio-Rad</italic>, Calif&#x000f3;rnia, EUA). As medi&#x000e7;&#x000f5;es de glicose, creatinina urin&#x000e1;ria e RAC foram realizadas no analisador autom&#x000e1;tico Dimension RxL Max&#x000ae; (<italic>Siemens Healthcare Diagnostics</italic>, Malvern, EUA). O uKIM-1 foi analisado por kits comerciais de ELISA em sandu&#x000ed;che (<italic>R&#x00026;D systems</italic>, Minneapolis, MN, EUA). A insulina foi medida com o analisador Cobas&#x000ae; 6000 (<italic>Roche Diagnostics</italic>, EUA). O HOMA-IR foi calculado pela equa&#x000e7;&#x000e3;o: insulina em jejum [&#x003bc;U/l] x glucose em jejum [mmol/l]/22,5. O &#x000ed;ndice triglic&#x000e9;rides-glicose (TyG) foi determinado pela equa&#x000e7;&#x000e3;o: ln [triglic&#x000e9;rides em jejum (mg/dl) x glicose em jejum (mg/dl)]/2. A taxa de filtra&#x000e7;&#x000e3;o glomerular (TFGe) foi estimada utilizando a equa&#x000e7;&#x000e3;o de creatinina da <italic>Chronic Kidney Disease Epidemiology Collaboration</italic> (CKD-EPI).</p><p>Os dados foram apresentados como m&#x000e9;dia e desvio padr&#x000e3;o (DP) para vari&#x000e1;veis cont&#x000ed;nuas. A distribui&#x000e7;&#x000e3;o das vari&#x000e1;veis foi testada por meio do teste de Kolmogorov-Smirnov. O teste <italic>t</italic> de Student foi empregado para comparar vari&#x000e1;veis cont&#x000ed;nuas, enquanto o teste qui-quadrado foi utilizado para vari&#x000e1;veis categ&#x000f3;ricas. As diferen&#x000e7;as estat&#x000ed;sticas entre os grupos tamb&#x000e9;m foram avaliadas pelo teste <italic>t</italic> de Student. Um valor de p &#x0003c; 0,05 foi considerado estatisticamente significativo. As an&#x000e1;lises estat&#x000ed;sticas foram realizadas com o software GraphPad (San Diego, CA, EUA).</p></sec><sec sec-type="results"><title>Resultados</title><p>Os dados gerais da popula&#x000e7;&#x000e3;o do estudo est&#x000e3;o descritos na <xref rid="T2" ref-type="table">Tabela 1</xref>. Neste estudo, os pacientes de ambos os grupos apresentaram valores de RAC dentro da faixa de normalidade, o que, em teoria, indicaria a aus&#x000ea;ncia de DRD. No entanto, embora a RAC seja um dos crit&#x000e9;rios adotados para o diagn&#x000f3;stico de DRD, esta patologia pode ocorrer mesmo com resultados normais de RAC. O grupo com HOMA-IR &#x02265; 2,77 apresentou um valor de uKIM-1 de 113,3 &#x000b1; 65,0 ng/g creatinina, superior aos resultados encontrados para o grupo com HOMA-IR &#x0003c; 2,77 que, por sua vez, apresentou uma concentra&#x000e7;&#x000e3;o de uKIM-1 de 84,4 &#x000b1; 50,0 ng/g creatinina (<xref rid="F2" ref-type="fig">Figura 1</xref>). Essa diferen&#x000e7;a representou um incremento de aproximadamente 35% nos resultados de uKIM-1 no grupo com maior resist&#x000ea;ncia insul&#x000ed;nica, sendo estatisticamente significativa. Al&#x000e9;m disso, pacientes com uKIM-1 &#x0003e;109 ng/g creatinina foram observados em ambos os grupos, com uma preval&#x000ea;ncia de 40% no grupo HOMA-IR &#x02265; 2,77 e 15,6|% no grupo HOMA-IR &#x0003c; 2,77 (p = 0,0193).</p><table-wrap position="float" id="T2"><label>Tabela 1</label><caption><title>Dados epidemiol&#x000f3;gicos e bioqu&#x000ed;micos dos participantes do estudo</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">&#x000cd;ndice HOMA-IR &#x0003c; 2,77</th><th align="center" valign="top" rowspan="1" colspan="1">&#x000cd;ndice HOMA-IR &#x02265; 2,77</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Idade (anos)</td><td align="center" valign="top" rowspan="1" colspan="1">63,7 &#x000b1; 11,0</td><td align="center" valign="top" rowspan="1" colspan="1">56,6 &#x000b1; 13,9</td><td align="center" valign="top" rowspan="1" colspan="1">0,018</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IMC (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">27,8 &#x000b1; 4,3</td><td align="center" valign="top" rowspan="1" colspan="1">33,2 &#x000b1; 5,6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0,001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Homens<break/>Uso de anti-hipertensivo oral</td><td align="center" valign="top" rowspan="1" colspan="1">13 (40,6%)<break/>24 (75%)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (30,0%)<break/>34 (68%)</td><td align="center" valign="top" rowspan="1" colspan="1">0,322<break/>0,496</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glicose de jejum (mmol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">119,8 &#x000b1; 30,7</td><td align="center" valign="top" rowspan="1" colspan="1">138,4 &#x000b1; 39,6</td><td align="center" valign="top" rowspan="1" colspan="1">0,028</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c (%)</td><td align="center" valign="top" rowspan="1" colspan="1">6,7 &#x000b1; 1,2</td><td align="center" valign="top" rowspan="1" colspan="1">7,9 &#x000b1; 2,0</td><td align="center" valign="top" rowspan="1" colspan="1">0,003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Insulina (uUI/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">6,1 &#x000b1; 2,1</td><td align="center" valign="top" rowspan="1" colspan="1">21,5 &#x000b1; 8,9</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0,001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Colesterol total (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">174,2 &#x000b1; 33,6</td><td align="center" valign="top" rowspan="1" colspan="1">170,8 &#x000b1; 27,9</td><td align="center" valign="top" rowspan="1" colspan="1">0,627</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Colesterol HDL (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">53,6 &#x000b1; 12,0</td><td align="center" valign="top" rowspan="1" colspan="1">44,6 &#x000b1; 11,0</td><td align="center" valign="top" rowspan="1" colspan="1">0,001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triglicer&#x000ed;deos (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">121,9 &#x000b1; 56,7</td><td align="center" valign="top" rowspan="1" colspan="1">140,4 &#x000b1; 60,2</td><td align="center" valign="top" rowspan="1" colspan="1">0,177</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinina (&#x000b5;mol/L)</td><td align="center" valign="top" rowspan="1" colspan="1">1,1 &#x000b1; 0,5</td><td align="center" valign="top" rowspan="1" colspan="1">0,9 &#x000b1; 0,4</td><td align="center" valign="top" rowspan="1" colspan="1">0,095</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TyG</td><td align="center" valign="top" rowspan="1" colspan="1">4,7 &#x000b1; 0,2</td><td align="center" valign="top" rowspan="1" colspan="1">4,9 &#x000b1; 0,3</td><td align="center" valign="top" rowspan="1" colspan="1">0,008</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HOMA-IR</td><td align="center" valign="top" rowspan="1" colspan="1">1,7 &#x000b1; 0,5</td><td align="center" valign="top" rowspan="1" colspan="1">7,3 &#x000b1; 3,7</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;0,001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CKD-EPI (mL/min/1,73m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">73,1 &#x000b1; 19,8</td><td align="center" valign="top" rowspan="1" colspan="1">76,02 &#x000b1; 21,1</td><td align="center" valign="top" rowspan="1" colspan="1">0,539</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">uCrea (mmol/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">0,9 &#x000b1; 0,2</td><td align="center" valign="top" rowspan="1" colspan="1">0,9 &#x000b1; 0,2</td><td align="center" valign="top" rowspan="1" colspan="1">0,477</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RAC (mg/g creat)</td><td align="center" valign="top" rowspan="1" colspan="1">7,5 &#x000b1; 4,3</td><td align="center" valign="top" rowspan="1" colspan="1">9,0 &#x000b1; 6,3</td><td align="center" valign="top" rowspan="1" colspan="1">0,242</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">uKIM-1(ng/g creat)</td><td align="center" valign="top" rowspan="1" colspan="1">84,4 &#x000b1; 50,0</td><td align="center" valign="top" rowspan="1" colspan="1">113,3 &#x000b1; 65,0</td><td align="center" valign="top" rowspan="1" colspan="1">0,044</td></tr></tbody></table><table-wrap-foot><fn id="T2FN1"><p>Abrevia&#x000e7;&#x000f5;es &#x02013; IMC, &#x000ed;ndice de massa corporal; HbA1c, hemoglobina glicada; HDL, colesterol de alta densidade; &#x000ed;ndice TyG, &#x000ed;ndice triglic&#x000e9;rides-glicose; HOMA-IR, Modelo de Homeostase da Resist&#x000ea;ncia &#x000e0; Insulina; taxa CFD-EPI, equa&#x000e7;&#x000e3;o de creatinina da <italic>Chronic Kidney Disease Epidemiology Collaboration</italic>; uCrea, creatinina urin&#x000e1;ria; RAC, rela&#x000e7;&#x000e3;o albumina/creatinina; uKIM-1, mol&#x000e9;cula-1 de les&#x000e3;o renal urin&#x000e1;ria. Notas &#x02013; Os dados cont&#x000ed;nuos s&#x000e3;o expressos em m&#x000e9;dia &#x000b1; desvio padr&#x000e3;o. Os dados categ&#x000f3;ricos s&#x000e3;o expressos em n&#x000fa;mero de indiv&#x000ed;duos e porcentagem (entre par&#x000ea;nteses).</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2"><label>Figura 1</label><caption><title>Valores de uKIM-1 em pacientes com DM2 com &#x000ed;ndice HOMA-IR &#x0003c; 2,77 e HOMA-IR &#x02265; 2,77. Os dados s&#x000e3;o expressos como m&#x000e9;dia &#x000b1; desvio padr&#x000e3;o. As diferen&#x000e7;as estat&#x000ed;sticas entre os grupos foram avaliadas usando o teste <italic>t</italic> de Student.</title></caption><graphic xlink:href="2175-8239-jbn-47-3-e20240123-gf02" position="float"/></fig></sec><sec sec-type="discussion"><title>Discuss&#x000e3;o</title><p>Sabe-se que os efeitos da hiperglicemia est&#x000e3;o associados a diversas disfun&#x000e7;&#x000f5;es que podem causar danos &#x000e0;s estruturas renais e contribuir para o desenvolvimento de DRD. A etiologia dessa condi&#x000e7;&#x000e3;o baseia-se em les&#x000f5;es causadas pela hiperfiltra&#x000e7;&#x000e3;o da barreira de filtra&#x000e7;&#x000e3;o glomerular, estresse oxidativo e expans&#x000e3;o mesangial glomerular, fatores associados ao controle glic&#x000ea;mico inadequado e ao consequente aumento da concentra&#x000e7;&#x000e3;o da RAC<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup>. Dessa forma, a avalia&#x000e7;&#x000e3;o do estado cl&#x000ed;nico do paciente por meio de exames laboratoriais &#x000e9; fundamental. Nesse contexto, o uKIM-1 pode ser um indicador relevante, associado a marcadores de resist&#x000ea;ncia &#x000e0; insulina, como o &#x000ed;ndice HOMA-IR, uma vez que o KIM-1 pode contribuir para a detec&#x000e7;&#x000e3;o de altera&#x000e7;&#x000f5;es tubulares antes do aumento da concentra&#x000e7;&#x000e3;o da RAC.</p><p>O padr&#x000e3;o ouro para o diagn&#x000f3;stico da DRD &#x000e9; a dosagem da RAC, um marcador de dano glomerular cujo aumento constitui o primeiro sinal de insufici&#x000ea;ncia renal<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup>. Entretanto, estudos t&#x000ea;m indicado a presen&#x000e7;a de altera&#x000e7;&#x000f5;es histol&#x000f3;gicas na membrana basal glomerular em amostras de bi&#x000f3;psia mesmo em concentra&#x000e7;&#x000f5;es de RAC dentro da faixa de normalidade<sup>
<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>
</sup>.</p><p>Considerando que os efeitos da les&#x000e3;o renal causada pelo DM2 podem levar a complica&#x000e7;&#x000f5;es graves, &#x000e9; importante fazer a triagem dos pacientes mais suscet&#x000ed;veis ou daqueles que se encontram nas fases iniciais da doen&#x000e7;a. O diagn&#x000f3;stico precoce permitiria a ado&#x000e7;&#x000e3;o de medidas para prevenir o desenvolvimento da DRD e evitar consequ&#x000ea;ncias graves e irrevers&#x000ed;veis<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup>.</p><p>Por conseguinte, tem-se buscado identificar novos marcadores capazes de detectar les&#x000f5;es renais precoces, incluindo o uKIM-1<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>. A utiliza&#x000e7;&#x000e3;o desta prote&#x000ed;na como marcador de RTDAIR oferece muitas vantagens, como a capacidade de indicar a presen&#x000e7;a de les&#x000f5;es tubulointersticiais, uma vez que as les&#x000f5;es tubulares frequentemente precedem as les&#x000f5;es glomerulares. Al&#x000e9;m disso, em condi&#x000e7;&#x000f5;es normais, o uKIM-1 &#x000e9; indetect&#x000e1;vel na urina, o que contribui para o aumento da especificidade deste marcador<sup>
<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>
</sup>.</p><p>O presente estudo apresenta algumas limita&#x000e7;&#x000f5;es, incluindo o n&#x000fa;mero relativamente baixo de participantes, a aus&#x000ea;ncia de c&#x000e1;lculo do tamanho amostral e a falta de alguns dados relacionados aos tratamentos farmacol&#x000f3;gico e n&#x000e3;o farmacol&#x000f3;gico. No entanto, demonstramos que indiv&#x000ed;duos com maior resist&#x000ea;ncia &#x000e0; insulina podem apresentar dano tubular aumentado, conforme evidenciado pelo aumento de uKIM-1, mesmo na aus&#x000ea;ncia de dano glomerular (de acordo com os valores normais de RAC). Como a hiperglicemia &#x000e9; um dos principais fatores contribuintes para o desenvolvimento de les&#x000e3;o tubular renal, indiv&#x000ed;duos com maior resist&#x000ea;ncia &#x000e0; insulina tendem a apresentar um pior controle glic&#x000ea;mico<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup>.</p></sec><sec sec-type="conclusions"><title>Conclus&#x000e3;o</title><p>Neste estudo, observamos que pacientes com maior resist&#x000ea;ncia &#x000e0; insulina, indicada pelos valores de HOMA-IR, apresentaram concentra&#x000e7;&#x000f5;es mais elevadas de uKIM-1, o que pode indicar a ocorr&#x000ea;ncia de les&#x000e3;o tubular renal dentre os pacientes normoalbumin&#x000fa;ricos. O uKIM-1, juntamente com a RAC, pode ser fundamental para identificar a presen&#x000e7;a de les&#x000f5;es em diferentes locais do n&#x000e9;fron, como o glom&#x000e9;rulo e os t&#x000fa;bulos renais, respectivamente. Portanto, a an&#x000e1;lise laboratorial do uKIM-1 apresenta potencial de contribuir para uma avalia&#x000e7;&#x000e3;o mais detalhada e aprofundada das altera&#x000e7;&#x000f5;es ocorridas a n&#x000ed;vel tubular renal.</p></sec></body><back><ack><title>Agradecimentos</title><p>Este estudo foi apoiado por bolsas de estudo da Funda&#x000e7;&#x000e3;o Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior (CAPES; bolsa no. 88887.921363/2023-00).</p></ack><sec sec-type="data-availability" specific-use="data-available-upon-request"><title>Disponibilidade de Dados</title><p>Os dados que fundamentam os achados deste manu-scrito est&#x000e3;o dispon&#x000ed;veis com o autor correspondente e podem ser disponibilizados mediante solicita&#x000e7;&#x000e3;o.</p></sec></back></sub-article></article>